|
1
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
2
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: from genes to environment. Nature Rev
Cancer. 6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poon D, Anderson BO, Chen LT, Tanaka K,
Lau WY, Van Cutsem E, et al: Management of hepatocellular carcinoma
in Asia: consensus statement from the Asian Oncology Summit 2009.
Lancet Oncol. 10:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruix J and Sherman M; Practice Guidelines
Committee, American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar
|
|
6
|
Coleman WB: Mechanism of human
hepatocarcinogenesis. Curr Mol Med. 3:573–588. 2003. View Article : Google Scholar
|
|
7
|
Caldwell S and Park SH: The epidemiology
of hepatocellular cancer: from the perspectives of public health
problem to tumor biology. J Gastroenterol. 44(Suppl 19): 96–101.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bosch FX, Ribes J and Borràs J:
Epidemiology of primary liver cancer. Semin Liver Dis. 19:271–285.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tung-Ping Poon R, Fan ST and Wong J: Risk
factors, prevention, and management of postoperative recurrence
after resection of hepatocellular carcinoma. Ann Surg. 232:10–24.
2000.PubMed/NCBI
|
|
10
|
Portolani N, Coniglio A, Ghidoni S,
Giovanelli M, Benetti A, Tiberio GA and Giulini SM: Early and late
recurrence after liver resection for hepatocellular carcinoma:
prognostic and therapeutic implications. Ann Surg. 243:229–235.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hatanaka Y, Uratani Y, Takiguchi-Hayashi
K, Omori A, Sato K, Miyamoto M and Arimatsu Y: Intracortical
regionality represented by specific transcription for a novel
protein, latexin. Eur J Neurosci. 6:973–982. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Q, Yu L, Gao J, Fu Q, Zhang J, Zhang
P, Chen J and Zhao S: Cloning, tissue expression pattern and
genomic organization of latexin, a human homologue of rat
carboxypeptidase A inhibitor. Mol Biol Rep. 27:241–246. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aagaard A, Listwan P, Cowieson N, Huber T,
Ravasi T, Wells CA, Flanagan JU, Kellie S, Hume DA, Kobe B and
Martin JL: An inflammatory role for the mammalian carboxypeptidase
inhibitor latexin: relationship to cystatins and the tumor
suppressor TIG1. Structure. 13:309–317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pallarès I, Bonet R, García-Castellanos R,
Ventura S, Avilés FX, Vendrell J and Gomis-Rüth FX: Structure of
human carboxypeptidase A4 with its endogenous protein inhibitor,
latexin. Proc Natl Acad Sci USA. 102:3978–3983. 2005.PubMed/NCBI
|
|
15
|
Jing C, El-Ghany MA, Beesley C, Foster CS,
Rudland PS, Smith P and Ke Y: Tazarotene-induced gene 1 (TIG1)
expression in prostate carcinomas and its relationship to
tumorigenicity. J Natl Cancer Inst. 94:482–490. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang Y, Jansen M, Aronow B, Geiger H and
Van Zant G: The quantitative trait gene latexin influences the size
of the hematopoietic stem cell population in mice. Nat Genet.
39:178–188. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mitsunaga K, Kikuchi J, Wada T and
Furukawa Y: Latexin regulates the abundance of multiple cellular
proteins in hematopoietic stem cells. J Cell Physiol.
227:1138–1147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Van Zant G and Liang Y: Natural genetic
diversity as a means to uncover stem cell regulatory pathways. Ann
NY Acad Sci. 1176:170–177. 2009.PubMed/NCBI
|
|
19
|
Ke Y, Xu GW, Hagiwara K, Zhang JM, Ning T,
Wang B, Su XL, Feng LY, Lu GR, Lu YY and Harris CC: Isolation and
sequencing of the target genes induced by chemical carcinogen.
Science in China (Series C). 26:85–91. 1996.
|
|
20
|
Elledge SJ: Cell cycle checkpoints:
preventing an identity crisis. Science. 274:1664–1672. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Basang Z, Ding H, et al: Latexin
expression is downregulated in human gastric carcinomas and
exhibits tumor suppressor potential. BMC Cancer. 11:111–121.
2011.PubMed/NCBI
|
|
23
|
Greaves M and Maley CC: Clonal evolution
in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Porter PL, Malone KE, Heagerty PJ, et al:
Expression of cell-cycle regulators p27Kip1 and cyclin
E, alone and in combination, correlate with survival in young
breast cancer patients. Nat Med. 3:222–225. 1997.
|
|
25
|
Eastham JA, Hall SJ, Sehgal I, et al: In
vivo gene therapy with p53 or p21 adenovirus for
prostate cancer. Cancer Res. 55:5151–5155. 1995.PubMed/NCBI
|
|
26
|
Craig C, Wersto R, Kim M, et al: A
recombinant adenovirus expressing p27Kip1 induces cell
cycle arrest and loss of cyclin-Cdk activity in human breast cancer
cells. Oncogene. 14:2283–2289. 1997.PubMed/NCBI
|
|
27
|
Chen J, Willingham T, Shuford M, et al:
Effects of ectopic overexpression of p21WAF1/CIP1 on
aneuploidy and the malignant phenotype of human brain tumor cells.
Oncogene. 13:1395–1403. 1996.PubMed/NCBI
|
|
28
|
Hannon GJ and Beach D: p15INK4B
is a potential effector of TGF-β-induced cell cycle arrest. Nature.
371:257–261. 1994.
|
|
29
|
Guan KL, Jenkins CW, Li Y, et al: Growth
suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6
inhibitor, correlates with wild-type pRb function. Genes Dev.
8:2939–2952. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hirai H, Roussel MF, Kato JY, et al: Novel
INK4 proteins, p19 and p18, are specific inhibitors of the cyclin
D-dependent kinases CDK4 and CDK6. Mol Cell Biol. 15:2672–2681.
1995.PubMed/NCBI
|
|
31
|
Chan FK, Zhang J, Cheng L, et al:
Identification of human and mouse p19, a novel CDK4 and CDK6
inhibitor with homology to p16ink4. Mol Cell Biol. 15:2682–2688.
1995.PubMed/NCBI
|
|
32
|
Sherr CJ and Roberts JM: CDK inhibitors:
positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kiviharju-af Hällström TM, Jäämaa S,
Mönkkönen M, et al: Human prostate epithelium lacks Wee1A-mediated
DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci USA.
104:7211–7216. 2007.PubMed/NCBI
|
|
34
|
Yoshida T, Tanaka S, Mogi A, et al: The
clinical significance of Cyclin B1 and Wee1 expression in
non-small-cell lung cancer. Ann Oncol. 15:252–256. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Quelle DE, Ashmun RA, Shurtleff SA, et al:
Overexpression of mouse D-type cyclins accelerates G1 phase in
rodent fibroblasts. Genes Dev. 7:1559–1571. 1993. View Article : Google Scholar : PubMed/NCBI
|
